Victory for PULSYS delivery platform; Calibra gains clearance for new insulin patch-pen;

> Victory Pharma, based in San Diego, has completed its acquisition of MiddleBrook Pharmaceuticals and its PULSYS drug-delivery platform, which delivers drug to treat tonsillitis or pharyngitis at set intervals over a 24-hour period. Release

> Calibra Medical has been cleared by the FDA to market its Finesse insulin patch-pen for up to three-day use with Novo Nordisk's Novolog rapid acting insulin. The patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time and correction bolus insulin. Release

> Researchers at the Michigan Nanotechnology Institute for Medicine and Biological Sciences, including nanotech pioneer James Baker, have cooked up a dendrimer conjugated with riboflavin that appears to show promise in targeted cancer drug delivery. Abstract

> Drug delivery job of the week: Postdoc in brain drug delivery at the University of Cincinnati. "The successful candidate will work on delivery of SiRNA and DNA decoy to the brain." Listing

> Available for licensing at the University of Texas at Austin: Faster, less expensive manufacturing process for microtubes in drug delivery devices. Description

And Finally... Remember those "Fantastic Voyage" micro- and nanomachines that scientists a few years ago said were impossible to develop? They're possible. They're being developed. Nanowerk has an excellent review. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.